MyoKardia, Inc. (MYOK) CEO Sells $172,989.00 in Stock

MyoKardia, Inc. (NASDAQ:MYOK) CEO Anastasios Gianakakos sold 4,300 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $40.23, for a total transaction of $172,989.00. Following the completion of the sale, the chief executive officer now directly owns 513,417 shares in the company, valued at $20,654,765.91. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Anastasios Gianakakos also recently made the following trade(s):

  • On Wednesday, October 4th, Anastasios Gianakakos sold 4,300 shares of MyoKardia stock. The shares were sold at an average price of $40.86, for a total transaction of $175,698.00.
  • On Tuesday, September 5th, Anastasios Gianakakos sold 4,300 shares of MyoKardia stock. The shares were sold at an average price of $43.02, for a total transaction of $184,986.00.

MyoKardia, Inc. (NASDAQ MYOK) opened at $38.20 on Friday. MyoKardia, Inc. has a 52-week low of $10.55 and a 52-week high of $49.55.

MyoKardia (NASDAQ:MYOK) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.42). The firm had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. MyoKardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The company’s revenue was up 58.6% on a year-over-year basis. During the same period last year, the firm posted ($0.35) EPS. sell-side analysts forecast that MyoKardia, Inc. will post -1.62 earnings per share for the current fiscal year.

WARNING: This piece was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/11/11/myokardia-inc-myok-ceo-sells-172989-00-in-stock.html.

A number of equities research analysts have commented on the stock. TheStreet downgraded shares of MyoKardia from a “c” rating to a “d+” rating in a research report on Friday, November 3rd. Zacks Investment Research raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Wedbush reissued an “outperform” rating and issued a $51.00 price objective on shares of MyoKardia in a research report on Wednesday, September 20th. Credit Suisse Group reissued an “outperform” rating and issued a $55.00 price objective (up from $45.00) on shares of MyoKardia in a research report on Tuesday, September 19th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $65.00 price objective (up from $45.00) on shares of MyoKardia in a research report on Monday, August 21st. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. MyoKardia presently has an average rating of “Buy” and a consensus target price of $55.00.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its position in shares of MyoKardia by 2.5% in the 2nd quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 455 shares during the last quarter. American International Group Inc. grew its position in shares of MyoKardia by 18.8% in the 3rd quarter. American International Group Inc. now owns 12,735 shares of the biotechnology company’s stock valued at $546,000 after buying an additional 2,018 shares during the last quarter. Fiduciary Trust Co. grew its position in shares of MyoKardia by 7.2% in the 2nd quarter. Fiduciary Trust Co. now owns 30,612 shares of the biotechnology company’s stock valued at $401,000 after buying an additional 2,058 shares during the last quarter. Rhumbline Advisers grew its position in shares of MyoKardia by 12.4% in the 3rd quarter. Rhumbline Advisers now owns 20,788 shares of the biotechnology company’s stock valued at $891,000 after buying an additional 2,299 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in shares of MyoKardia by 5.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,680 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 2,394 shares during the last quarter. 43.67% of the stock is currently owned by hedge funds and other institutional investors.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply